Replies to post #143881 on Biotech Values

[genisi]

Seems that AGN is no longer a potential suitor for Ophthotech as they have the dual anti-VEGF-A/PDGF-B DARPin (MP0260) that we amusingly predicted in #msg-76614988. REGN might not need Ophthotech as they are also working on their own anti-PDGF:

Over the last several years, our scientists have also been exploring the role of platelet-derived growth factor, or PDGF, in angiogenesis. We currently have a high affinity PDGF antibody in pre-clinical development that we expect to be in the clinic in 2013. As a reminder, Sanofi has certain option rights to our antibodies.

http://seekingalpha.com/article/747551-regeneron-pharmaceuticals-ceo-discusses-q2-2012-results-earnings-call-transcript?page=6